Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg.
COVID-19
antibody
infection
multiple sclerosis
seroprevalence
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Dec 2020
16 Dec 2020
Historique:
received:
26
11
2020
revised:
09
12
2020
accepted:
13
12
2020
entrez:
19
12
2020
pubmed:
20
12
2020
medline:
20
12
2020
Statut:
epublish
Résumé
We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates. In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher's exact test, chi square test, or McNemar's test, as appropriate, to evaluate between-group differences. We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) ( MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression.
Sections du résumé
BACKGROUND
BACKGROUND
We compared the prevalence of SARS-CoV-2 IgG/IgM in multiple sclerosis (MS), low-risk, and high-risk populations and explored possible clinical correlates.
METHODS
METHODS
In this cross-sectional study, we recruited MS patients, low-risk (university staff from non-clinical departments), and high-risk individuals (healthcare staff from COVID-19 wards) from 11 May to 15 June 2020. We used lateral flow immunoassay to detect SARS-CoV-2 IgG and IgM. We used t-test, Fisher's exact test, chi square test, or McNemar's test, as appropriate, to evaluate between-group differences.
RESULTS
RESULTS
We recruited 310 MS patients (42.3 ± 12.4 years; females 67.1%), 862 low-risk individuals (42.9 ± 13.3 years; females 47.8%), and 235 high-risk individuals (39.4 ± 10.9 years; females 54.5%). The prevalence of SARS-CoV-2 IgG/IgM in MS patients (n = 9, 2.9%) was significantly lower than in the high-risk population (n = 25, 10.6%) (
CONCLUSIONS
CONCLUSIONS
MS patients have similar risk of SARS-CoV-2 infection to the general population, and can be asymptomatic from COVID-19, also if using treatments with systemic immunosuppression.
Identifiants
pubmed: 33339402
pii: jcm9124066
doi: 10.3390/jcm9124066
pmc: PMC7766741
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Eur J Epidemiol. 2020 Apr;35(4):331-333
pubmed: 32318914
Open Forum Infect Dis. 2018 Jul 16;5(8):ofy174
pubmed: 30094293
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Diagnostics (Basel). 2020 May 19;10(5):
pubmed: 32438677
Mult Scler Relat Disord. 2020 Jul;42:102185
pubmed: 32408147
J Microbiol Immunol Infect. 2020 May 15;:
pubmed: 32425996
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Lancet Neurol. 2020 Jun;19(6):481-482
pubmed: 32359409
Int J Environ Res Public Health. 2020 May 13;17(10):
pubmed: 32414017
JAMA Neurol. 2020 Jul 1;77(7):820-828
pubmed: 32364569
Mult Scler. 2020 Sep;26(10):1163-1171
pubmed: 32772807
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(5):
pubmed: 32503092
J Med Virol. 2020 Oct;92(10):1735-1738
pubmed: 32243608
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
Eur J Neurol. 2020 Sep;27(9):e50-e51
pubmed: 32402100
J Infect. 2020 Aug;81(2):e91-e92
pubmed: 32417311
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
Mult Scler. 2020 Sep;26(10):1134-1136
pubmed: 32924837
J Neurol Neurosurg Psychiatry. 2020 Aug 27;:
pubmed: 32855290
Neurology. 2017 Aug 8;89(6):555-562
pubmed: 28687718
Mult Scler. 2020 Sep;26(10):1256-1260
pubmed: 32662742
Ann Neurol. 2020 Jun;87(6):794-797
pubmed: 32383812
Mult Scler Relat Disord. 2020 Oct;45:102452
pubmed: 32823148
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Neurology. 2015 Jul 21;85(3):240-7
pubmed: 26019190
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1050-1056
pubmed: 29602795
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Infection. 2020 Aug;48(4):631-634
pubmed: 32524515
Mult Scler Relat Disord. 2020 Sep;44:102282
pubmed: 32554288